Cibc World Markets Corp Makes New $157,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Cibc World Markets Corp purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 23,286 shares of the company’s stock, valued at approximately $157,000.

Several other large investors have also made changes to their positions in RXRX. Farther Finance Advisors LLC raised its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after acquiring an additional 1,353 shares in the last quarter. Wedmont Private Capital increased its stake in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 28.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock valued at $69,000 after purchasing an additional 2,235 shares in the last quarter. Green Alpha Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after purchasing an additional 2,346 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Recursion Pharmaceuticals by 5.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after purchasing an additional 2,667 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $5.97 on Friday. The stock has a market capitalization of $2.40 billion, a PE ratio of -3.90 and a beta of 0.85. The stock has a 50-day simple moving average of $7.46 and a 200 day simple moving average of $7.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company posted ($0.42) earnings per share. The firm’s revenue was down 57.8% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.